Web Exclusives

This infographic illustrates key findings from the first-of-its-kind study to examine outcomes, evaluate analytics, identify barriers/challenges, analyze performance improvement processes, and identify opportunities for future research.
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.
At the 2017 Association of Community Cancer Centers Annual Meeting, Tricia Strusowski, RN, MS, Manager, Oncology Solutions, LLC, and project lead of the AONN+ Standardized Metrics Task Force, discussed how the newly released AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.

Results 1 - 7 of 7

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State